Allergan Receives a Buy from Credit Suisse

Credit Suisse analyst Vamil Divan maintained a Buy rating on Allergan (NYSE: AGN) yesterday and set a price target of $213. The company’s shares closed yesterday at $177.15.

According to, Divan is a 1-star analyst with an average return of -1.3% and a 47.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Eli Lilly & Co.

Currently, the analyst consensus on Allergan is a Moderate Buy with an average price target of $204.11.

See today’s analyst top recommended stocks >>

Based on Allergan’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $286 million. In comparison, last year the company had a GAAP net loss of $726 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.

From Our Partners